For the treatment of migraine with or without aura; the U.S. Food and Drug Administration has recently approved Eli Lilly’s Reyvow. Serotonin are brain receptors which acts in migraine, Reyvow is the migraine treatment which binds with serotonin receptors and depressing central nervous system activity.
Nick Kozauer, MD, is acting as a deputy director of the FDA’s Division of Neurology Product said in his statement that “Reyvow is a new option for the acute treatment of migraine, a painful condition that affects one in seven Americans.” He further said that “We know that the migraine community is interested in more treatment options and we continuing to work with stakeholders in order to promote the development of new therapies for the acute and preventive treatment of migraine.”
According to the survey of American Migraine Foundation, migraine affects about 36 million adults in the United States and about billions of peoples worldwide. Migraine initially causes pain and nausea but in addition to that migraine also causes blurriness, light sensitivity and visual disturbances known as aura.
In two double-blind, placebo-controlled studies which were involve 3,200 patients (peoples suffering from migraine) nearly; the effectiveness of Reyvow tablets was demonstrated. In one study, patients received 200mg of Reyvow and the patients of that study receive about 32% of pain relief after two hours of treatment but that compares to 15% taking a placebo which was enough to be considered statistically significant.
A neurology professor of Vanderbilt university and paid consultant to Lilly Jan Brandes, MD stated that “As a physician, I commonly treat patients who are looking for acute treatment options that offer the chance for pain freedom during migraine attacks and this approval is especially significant because migraine pain is so often severe and incapacitating”
Dizziness, fatigue, a burning or prickling sensation in the skin (paresthesia), and sedation was the most common side effects for Reyvow trails. FDA warns by labeling a caution saying that not to drive or operate machinery for at least eight hours after taking Reyvow. The Reyvow drug should also not be taken with other serotonin depressants or alcohol.
It should be remember that Reyvow is not approved for the preventive treatment of migraine.
The FDA has approved several new migraine therapies in recent years which include the injectable drugs to prevent migraine and neuromodulation devices that use electrical pulses to disrupt pain signals.
Migraine is a painful condition which can be triggered by various factors including lack of sleep or food, flashing or bright lights, hormonal changes, diet, and stress. Women are often three times more likely to suffer from migraine than man.